REFERENCES
- Martindale. The Extra Pharmacopoeia, J. E. F. Reynolds. 30, Pharmaceutical Press, London 1993
- Gaver R. C. Sem. Oncol. 1985; 12(suppl. 1)17–19
- Camaggi C. M. Cancer Chemother. Pharmacol. 1995; 36: 356–359
- Gaver R. C. Biopharm. Drug Dispos. 1986; 7: 35–46
- U.S. Pharmacopeial Convention. The United States Pharmacopeia 23/National Formulary 18. Author, Rockville, MD 1995
- U.S. Food and Drug Administration Guidance: statistical procedures for bioequivalence studies using a standard two-treatment crossover design, informal communication under 21 CFR 10.90(b)(a) (1992)
- Schuirmann D. J. J. Pharmacokinet. Biopharm. 1987; 15: 657–680
- Hauschke D., Steinijans V. W., Diletti E. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992; 28: 105–110
- Steinijans V. W., Sauter R., Hauschke D., Diletti E., Schall R., Luus H. G., Elze M., Blume H., Hoffmann C., Franke G., Siegmund W. Int. J. Clin. Pharmacol. Ther. 1995; 33: 427–430